ATXN1 and colorectal carcinoma: SCA1 participants progressed 2.64 times faster than SCA6 participants in the EUROSCA study (2.11 points per year vs. 0.8 point per year),16 1.87 times faster in the CRC study (1.61 vs. 0.86),17 and 1.24 times faster in a third study (1.23 vs. 0.99),11 whereas the progression was just 1.12 times faster in our study (1.11 vs. 0.99).